This invention generally relates to a plasma therapy device, and more specifically, to a cold plasma therapy device with a replaceable dielectric barrier.
Plasma as the fourth fundamental state of matter, is a neutral ionized gas composed of positively charged ions, electrons, and neutral particles. In common thermal plasma, all particles approach thermal equilibrium due to intensive collisions between electrons and heavy particles. The temperature in such plasma can reach several thousand degrees. On the other hand, there is another type of plasma in which electrons and heavy particles are in thermal non-equilibrium. In this case, the temperature of the heavy particles is much lower than that of the electrons. This type of plasma is called non-thermal plasma or cold plasma. The heavy particle temperature in cold plasma is typically between 25° C. and 45° C. The plasma discharge may take place in ambient air or in specially supplied gas flow. Many reactive species, including oxygen-based radicals, nitrogen-based radicals, and other components, are generated in the cold plasma. This complicated chemistry can lead to a variety of interactions between cold plasma and biological tissues, allowing the cold plasma to be used for biomedicine.
Dielectric barrier discharge (DBD), which involves electrical discharge between two electrodes separated by an insulating dielectric barrier, is one effective method to produce cold plasma. For biomedical applications, the living tissue is often employed as one of the electrodes, and the plasma discharge is produced between the dielectric barrier and the subject tissue. When the DBD device is used for treating different patients, it is highly desirable to replace the dielectric barrier between treatments to avoid cross-infection. Also, it is desirable to switch among different types of dielectric barriers for treating different medical conditions. This is because the effective treatment of one specific medical condition may require a specific combination of reactive species in the plasma discharge which in turn is affected by both the electrical characteristics of the subject tissue and the parameters of the dielectric barrier. Currently, there is no DBD plasma therapy device providing easily replaceable or switchable dielectric barriers.
It is the overall goal of the present invention to solve the above-mentioned problems and provide a DBD plasma therapy device with replaceable dielectric barrier for treating different patients with different medical conditions. The plasma therapy device is equipped with a variety of dielectric barriers. The dielectric barriers may have different electrical characteristics (which are determined by their materials as well as physical dimensions and shapes) to adapt for the treatment of different types of biological tissues. The dielectric barrier of the plasma therapy device can be replaced to avoid contamination and cross-infection. As an additional feature, the plasma device further comprises an optical sensor, such as a spectroscopic sensor, for monitoring the emission spectrum of the plasma discharge. The emission spectrum can be utilized to analyze the composition of the reactive species generated by the plasma discharge and provide feedback control to the plasma therapy device.
The accompanying figures where like reference numerals refer to identical or functionally similar elements throughout the separate views and which together with the detailed description below are incorporated in and form part of the specification, serve to further illustrate various embodiments and to explain various principles and advantages all in accordance with the present invention.
Skilled artisans will appreciate that elements in the figures are illustrated for simplicity and clarity and have not necessarily been drawn to scale. For example, the dimensions of some of the elements in the figures may be exaggerated relative to other elements to help to improve understanding of embodiments of the present invention.
Before describing in detail embodiments that are in accordance with the present invention, it should be observed that the embodiments reside primarily in combinations of method steps and apparatus components related to a cold plasma therapy device. Accordingly, the apparatus components and method steps have been represented where appropriate by conventional symbols in the drawings, showing only those specific details that are pertinent to understanding the embodiments of the present invention so as not to obscure the disclosure with details that will be readily apparent to those of ordinary skill in the art having the benefit of the description herein.
In this document, relational terms such as first and second, top and bottom, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. The terms “comprises,” “comprising,” or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. An element proceeded by “comprises . . . a” does not, without more constraints, preclude the existence of additional identical elements in the process, method, article, or apparatus that comprises the element.
Due to the diversity of the medical conditions and types of biological tissues (e.g., different body parts of the human or animal subject) to be treated as well as the variations from individual to individual, a customized treatment protocol with specific plasma density, reactive species composition, and dosage may be required to achieve the optimum therapeutic outcome. These plasma parameters are determined by the output voltage, repetition rate, duty cycle, and treatment time of the power supply 100, the composition of the gas in which the plasma discharge takes place, the distance between the second dielectric barrier 126 and the subject biological tissue 110, and also affected by the electrical characteristics (e.g., capacitance, resistance, inductance) of the subject biological tissue 110 and the second dielectric barrier 126, and the grounding condition of the subject biological tissue 110. The electrical characteristics of the biological tissue are further determined by its composition, volume, and humidity. The electrical characteristics of the second dielectric barrier 126 are mainly determined by its material (hence dielectric constant or relative permittivity) as well as its physical dimensions and shapes (especially thickness). The switchable second dielectric barrier 126 offers additional freedom for controlling the properties of the plasma discharge as its capacitance affects the discharge voltage, and its dielectric constant affects the streamer intensity, diameter, and density of the plasma discharge. The replaceable second dielectric barrier 126 also prevents contamination and/or cross-infection from one patient to another patient. A set of replaceable and switchable second dielectric barriers 126, each having different or similar electrical characteristics, can be provided to fulfill the above purposes of (i) controlling the properties of the plasma discharge, and (ii) preventing contamination and/or cross-infection. For practical applications, it is desirable to establish a correlation between the medical conditions and biological tissues to be treated and the corresponding parameters of the high voltage power supply 100 and the switchable second dielectric barrier 126, the gas flow composition, the distance between the DBD probe 120 and the subject tissue 110, etc. The correlation can be in the form of a look-up table, which is stored in the memory of the plasma therapy device. Before plasma treatment, the operator selects the optimum treatment protocol from the look-up table based on the conditions of the subject biological tissue. The high voltage power supply 100 and the DBD probe 120 are then adjusted to provide cold plasma therapy at the optimum treatment protocol.
To further ensure the therapeutic outcome, the plasma therapy device is equipped with an optical spectroscopic sensor 140 for monitoring the emission spectrum of the plasma discharge. Referring to
In another exemplary embodiment of the DBD plasma therapy device as shown in
In the foregoing specification, specific embodiments of the present invention have been described. However, one of ordinary skill in the art appreciates that various modifications and changes can be made without departing from the scope of the present invention as set forth in the claims below. The numerical values cited in the specific embodiment are illustrative rather than limiting. Accordingly, the specification and figures are to be regarded in an illustrative rather than a restrictive sense, and all such modifications are intended to be included within the scope of the present invention. The benefits, advantages, and solutions to problems, and any element(s) that may cause any benefit, advantage, or solution to occur or become more pronounced are not to be construed as a critical, required, or essential features or elements of any or all the claims. The invention is defined solely by the appended claims, including any amendments made during the pendency of this application and all equivalents of those claims as issued.
This application claims the inventions which were disclosed in Provisional Patent Application No. 62/874,228, filed Jul. 15, 2019, entitled “COLD PLASMA THERAPY DEVICE WITH REPLACEABLE DIELECTRIC BARRIER”. The benefit under 35 USC § 119(e) of the above mentioned United States Provisional Applications is hereby claimed, and the aforementioned application are hereby incorporated herein by reference.
Number | Date | Country | |
---|---|---|---|
62874228 | Jul 2019 | US |